Precision Medicines' Impact on Orphan Drug Designation.

We chose 2010 as a baseline as there was a 1.3‐fold increase in orphan drug designations over the previous year and the first year the FDA received >300 orphan drug designation requests, perhaps indicative of an increasing trend toward precision drug development approaches.

also in 63,971 other papers